Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

15.05.2023 - Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the ...

Related Keywords

New Jersey ,United States ,Baylor Biosciences ,Brian Ritchie ,Baylor Biosciences Inc ,Exchange Commission ,Jersey Technology Business Tax Certificate Transfer Program ,Clinical Program ,Clinical Program Highlights ,Interstitial Lung Disease ,Vigorous Physical Activity ,Quarter Ended March ,Financial Results ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Operations And Comprehensive Income ,